Beteiligte Stoffe
| Rolle | Name | HCID | Einwaage |
|---|
| Edukt | Mannitol | HCID 6251 | — |
| Edukt | Bendamustine | HCID 65628 | — |
| Edukt | Bendamustine Hydrochloride | HCID 77082 | — |
| Edukt | Ethanol bendamustine | HCID 131735415 | — |
| Lösungsmittel | Ethanol | HCID 702 | — |
| Lösungsmittel | Water | HCID 962 | — |
| Lösungsmittel | 1-Propanol | HCID 1031 | — |
| Produkt | Bendamustine Mannitol | HCID 131735414 | — |
Reaktionsschritte
Two batches (Batch 1 and Batch2) each one with a different pharmaceutical composition comprising solid dispersions in the form of dry powder and substantially free of hydrolysis degradants were produced. For each batch, two pre-drying intermediate compositions were formulated in separate containers. For Batch 1, the aqueous pre-drying composition was formulated consisting of 2380 mg of mannitol dissolved in 70 ml of water. The non-aqueous pre-drying composition was formulated by dissolving 1400 mg of bendamustine in 70 ml of n-propanol. For Batch 2, the aqueous pre-drying composition consisted of 1190 mg of mannitol dissolved in 70 ml of water. The non-aqueous pre-drying composition was formulated by dissolving 700 mg of bendamustine hydrochloride in 70 ml of ethanol. The ethanol/bendamustine solution could be cooled to minimize the extent of possible side reactions. Both feed pumps (see FIG. 10) were set in such a way that the ratio of excipient to API was 1.8 for Batch 1 and 1.9 for Batch 2. Tables 2 and 3 show the process parameters for Batch 1 and Batch 2.
Herkunft & Nachweise
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patentnummer | US09320730B2 |
|---|
| Quelldatensatz | uspto-grants-2016_04 |
|---|
| ORD ID | ord-1ca2d6f0ffff47bfafbea48a9b07efc3 |
|---|
| Quellennotiz | uspto-grants-2016_04 |
|---|